4058 – Anti-MPO

Highlights

• Use of IgG antibodies against myeloperoxidase (MPO)
• Ready-to-use (exception: wash buffer), color- and barcoded reagents
• Quality assured handling in routine laboratories
• Short incubation times (60 min / 30 min / 15 min) at room temperature
• Quantitative determination of IgG antibodies
• Acurrate diagnostic sensitivity and specificity shortly after onset of the disease
• Supports diagnosis of systemic vasculitides (SV)
• High precision and linearity within the measurement range
• CE marked
• Automatable

Intended Purpose

The Anti-MPO is a quantitative immunoassay for the determination of IgG antibodies against myeloperoxidase (MPO) in human serum. Specifically, clinicians use the Anti-MPO as an aid to diagnose systemic vasculitides (SV) in conjunction with other clinical and laboratory findings. Moreover, the immunoassay is designed for manual professional in vitro diagnostic use.

Diagnostic Relevance

In systemic vasculitis (SV), inflammation affects different blood vessel walls and causes morphological changes. Arteries and veins can both be affected simultaneously. Patients mainly experience general symptoms such as exhaustion, fever, and weight loss. However, the disease course varies depending on which types of vessels are involved.

Anti-neutrophil cytoplasmic antibodies (ANCA) play an important role in the serological diagnosis of SV. Clinicians usually determine these antibodies using indirect immunofluorescence (IIF) on ethanol-fixed human neutrophils, where the IIF pattern distinguishes cytoplasmic ANCA (cANCA) from perinuclear ANCA (pANCA). In IIF, MPO, a cationic protein found in azurophilic granules, mainly causes the pANCA pattern. In addition, MPO autoantibodies occur in a variety of vasculitides such as microscopic polyangiitis, Churg-Strauss syndrome, and polyarteritis nodosa. Importantly, researchers have found that autoantibodies against MPO correlate with idiopathic or vasculitis-associated necrotizing crescentic glomerulonephritis. They occur in about 70 % of patients with microscopic polyangiitis and 5–50 % of patients with Churg-Strauss syndrome

Publications

• Romero-Sánchez et al., (2020) Frequency of positive ANCA test in a population with clinical symptoms
• Bossuyt et al., (2020) Standardisation of PR3-ANCA and MPO-ANCA – evaluation of certified reference materials
• Sowa et al., (2016) Simultaneous comprehensive multiplex Ab analysis for rapidly progressive glomerulonephritis
• Sowa et al., (2014) Simultaneous Automated Screening and Confirmatory Testing for Vasculitis-Specific ANCA
• Holle et al., (2012) Comparative analysis of different commercial ELISA systems for the detection of ANCAs in ANCA-associated vasculitides
• Knütter et al., (2012) Automated interpretation of ANCA patterns-a new approach in the serology of ANCA associated vasculitis